Cargando…

Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study

Gestational diabetes mellitus (GDM) is a common metabolic disease that occurs during pregnancy, with the placenta playing an important role in its pathophysiology. Currently, the role of galectin-9 in the development of GDM is unknown. The aim of this study was to compare galectin-9 concentrations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pełech, Aleksandra, Ruszała, Monika, Niebrzydowska-Tatus, Magdalena, Bień, Katarzyna, Kimber-Trojnar, Żaneta, Czuba, Monika, Świstowska, Małgorzata, Leszczyńska-Gorzelak, Bożena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135713/
https://www.ncbi.nlm.nih.gov/pubmed/37189444
http://dx.doi.org/10.3390/biom13040697
_version_ 1785032044999344128
author Pełech, Aleksandra
Ruszała, Monika
Niebrzydowska-Tatus, Magdalena
Bień, Katarzyna
Kimber-Trojnar, Żaneta
Czuba, Monika
Świstowska, Małgorzata
Leszczyńska-Gorzelak, Bożena
author_facet Pełech, Aleksandra
Ruszała, Monika
Niebrzydowska-Tatus, Magdalena
Bień, Katarzyna
Kimber-Trojnar, Żaneta
Czuba, Monika
Świstowska, Małgorzata
Leszczyńska-Gorzelak, Bożena
author_sort Pełech, Aleksandra
collection PubMed
description Gestational diabetes mellitus (GDM) is a common metabolic disease that occurs during pregnancy, with the placenta playing an important role in its pathophysiology. Currently, the role of galectin-9 in the development of GDM is unknown. The aim of this study was to compare galectin-9 concentrations in healthy pregnant women and those with GDM. Galectin-9 levels were assessed in serum samples taken both just before and after delivery, as well as in urine samples collected in the postpartum period. Maternal body composition and hydration status were evaluated using the bioelectrical impedance analysis (BIA) method. There were no statistically significant differences in the concentration of galectin-9 in women with GDM compared to healthy pregnant women in their serum samples taken just before delivery, nor in their serum and urine samples collected in the early postpartum period. However, serum galectin-9 concentrations taken before delivery were positively correlated with BMI and parameters related to the amount of adipose tissue assessed in the early postpartum period. Additionally, there was a correlation between serum galectin-9 concentrations taken before and after delivery. Galectin-9 is unlikely to become a diagnostic marker for GDM. However, this subject requires further clinical research in larger groups.
format Online
Article
Text
id pubmed-10135713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101357132023-04-28 Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study Pełech, Aleksandra Ruszała, Monika Niebrzydowska-Tatus, Magdalena Bień, Katarzyna Kimber-Trojnar, Żaneta Czuba, Monika Świstowska, Małgorzata Leszczyńska-Gorzelak, Bożena Biomolecules Article Gestational diabetes mellitus (GDM) is a common metabolic disease that occurs during pregnancy, with the placenta playing an important role in its pathophysiology. Currently, the role of galectin-9 in the development of GDM is unknown. The aim of this study was to compare galectin-9 concentrations in healthy pregnant women and those with GDM. Galectin-9 levels were assessed in serum samples taken both just before and after delivery, as well as in urine samples collected in the postpartum period. Maternal body composition and hydration status were evaluated using the bioelectrical impedance analysis (BIA) method. There were no statistically significant differences in the concentration of galectin-9 in women with GDM compared to healthy pregnant women in their serum samples taken just before delivery, nor in their serum and urine samples collected in the early postpartum period. However, serum galectin-9 concentrations taken before delivery were positively correlated with BMI and parameters related to the amount of adipose tissue assessed in the early postpartum period. Additionally, there was a correlation between serum galectin-9 concentrations taken before and after delivery. Galectin-9 is unlikely to become a diagnostic marker for GDM. However, this subject requires further clinical research in larger groups. MDPI 2023-04-20 /pmc/articles/PMC10135713/ /pubmed/37189444 http://dx.doi.org/10.3390/biom13040697 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pełech, Aleksandra
Ruszała, Monika
Niebrzydowska-Tatus, Magdalena
Bień, Katarzyna
Kimber-Trojnar, Żaneta
Czuba, Monika
Świstowska, Małgorzata
Leszczyńska-Gorzelak, Bożena
Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title_full Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title_fullStr Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title_full_unstemmed Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title_short Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study
title_sort do serum galectin-9 levels in women with gestational diabetes and healthy ones differ before or after delivery? a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135713/
https://www.ncbi.nlm.nih.gov/pubmed/37189444
http://dx.doi.org/10.3390/biom13040697
work_keys_str_mv AT pełechaleksandra doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT ruszałamonika doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT niebrzydowskatatusmagdalena doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT bienkatarzyna doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT kimbertrojnarzaneta doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT czubamonika doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT swistowskamałgorzata doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy
AT leszczynskagorzelakbozena doserumgalectin9levelsinwomenwithgestationaldiabetesandhealthyonesdifferbeforeorafterdeliveryapilotstudy